<DOC>
	<DOCNO>NCT01000818</DOCNO>
	<brief_summary>An open-label , 3-period , fixed-sequence study panel 18 HIV-infected patient MK0518 part stable treatment regimen HIV .</brief_summary>
	<brief_title>A Study Evaluate Effect Famotidine Omeprazole MK0518 ( Raltegravir ) Pharmacokinetics Human Immunodeficiency Virus ( HIV ) -Infected Patients ( 0518-054 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patient Human immunodeficiency virus ( HIV ) positive Patient take MK0518 ( Raltegravir ) contain regimen Patient change his/her antiviral regimen last 2 week Patient reproductive potential agrees use acceptable method birth control Patients baseline health stable Patient history stroke chronic seizure . Patient history gastric bypass surgery Patient pregnant breastfeeding Patient consume excessive amount caffeinated beverage daily Patient major surgery , donate blood , participate another investigational study past 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Treatment experience</keyword>
</DOC>